Faculty Bibliography
Searched for:
in-biosketch:true
person:bangas01
Total Results:
803
The Burden of Atherosclerotic Cardiovascular Disease in South Asians Residing in Canada: A Reflection From the South Asian Heart Alliance
South Asians (SAs), originating from the Indian subcontinent (India, Pakistan, Sri Lanka, Bangladesh, Nepal, and Bhutan), represent one quarter of the global population and are the largest visible minority in Canada. SAs experience the highest rates of coronary artery disease in Canada. Although conventional cardiovascular risk factors remain predictive in SA, the excess risk is not fully explained by these risk factors alone. Abdominal obesity, metabolic syndrome, and insulin resistance likely contribute a greater risk in SAs than in other populations. The South Asian Heart Alliance has been recently formed to investigate and recommend the best strategies for the prevention of cardiometabolic disease in SAs in Canada. This topic review represents a comprehensive overview of the magnitude of cardiovascular disease in SAs in Canada, with a review of conventional and novel risk markers in the SA population. Both primary and secondary prevention strategies are suggested and when possible, adapted specifically for the SA population. The need for SAs and their healthcare professionals to be more aware of the problem and potential solutions, along with the need for population-specific research, is highlighted.
PMCID:7063609
PMID: 32159121
ISSN: 2589-790x
CID: 4349082
Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a united states based retrospective claims database analysis
PMID: 31665949
ISSN: 1941-837x
CID: 4162352
Meta-Analysis in the Mirror of its Quotations: Science, Scepticism, Scorn, and Sarcasm
PMID: 31633175
ISSN: 1522-9645
CID: 4146922
Journal of the American College of Cardiology. 2019:74(13):B175-B175.DOI: 10.1016/j.jacc.2019.08.233
Implantation of Thin-Strut Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With De Novo Coronary Artery Lesions: 2-Year Clinical and 6-Month Imaging Outcomes of the MeRes-1 Extend Trial [Meeting Abstract]
ISI:000487306300176
ISSN: 0735-1097
CID: 4124852
Journal of the American College of Cardiology. 2019:74(13):B802-B802.DOI: 10.1016/j.jacc.2019.08.965
Safety and Efficacy of Mechanical Circulatory Support With Impella or Intra-Aortic Balloon Pump for High-Risk Percutaneous Coronary Intervention and/or Cardiogenic Shock: Insights From a Network Meta-Analysis [Meeting Abstract]
ISI:000487306300803
ISSN: 0735-1097
CID: 4124892
Journal of the American College of Cardiology. 2019:74(13):B706-B706.DOI: 10.1016/j.jacc.2019.08.851
Antithrombotic Strategies After Transcatheter Aortic Valve Implantation: Insights From a Network Meta-Analysis [Meeting Abstract]
ISI:000487306300707
ISSN: 0735-1097
CID: 4124882
Journal of the American College of Cardiology. 2019:74(14):1823-1838.DOI: 10.1016/j.jacc.2019.08.1017
Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review
Chronic kidney disease (CKD) is a major risk factor for coronary artery disease (CAD). As well as their high prevalence of traditional CAD risk factors, such as diabetes and hypertension, persons with CKD are also exposed to other nontraditional, uremia-related cardiovascular disease risk factors, including inflammation, oxidative stress, and abnormal calcium-phosphorus metabolism. CKD and end-stage kidney disease not only increase the risk of CAD, but they also modify its clinical presentation and cardinal symptoms. Management of CAD is complicated in CKD patients, due to their likelihood of comorbid conditions and potential for side effects during interventions. This summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference on CAD and CKD (including end-stage kidney disease and transplant recipients) seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of CAD in CKD and to identify knowledge gaps, areas of controversy, and priorities for research.
PMID: 31582143
ISSN: 1558-3597
CID: 4116492
Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Chronic kidney disease (CKD) is a major risk factor for valvular heart disease (VHD). Mitral annular and aortic valve calcifications are highly prevalent in CKD patients and commonly lead to valvular stenosis and regurgitation, as well as complications including conduction system abnormalities and endocarditis. VHD, especially mitral regurgitation and aortic stenosis, is associated with significantly reduced survival among CKD patients. Knowledge related to VHD in the general population is not always applicable to CKD patients because the pathophysiology may be different, and CKD patients have a high prevalence of comorbid conditions and elevated risk for periprocedural complications and mortality. This Kidney Disease: Improving Global Outcomes (KDIGO) review of CKD and VHD seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of VHD in CKD by summarizing knowledge gaps, areas of controversy, and priorities for research.
PMID: 31543156
ISSN: 1523-1755
CID: 4105302
Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials
Background Kidney function decreases during the lifetime, and this decline is a powerful predictor of both kidney and cardiovascular outcomes. Statins lower cardiovascular risk, which may relate to beneficial effects on kidney function. We studied whether atorvastatin influences kidney function decline and assessed the association between individual kidney function slopes and cardiovascular outcome. Methods and Results Data were collected from 6 large atorvastatin cardiovascular outcome trials conducted in patients not selected for having kidney disease. Slopes of serum creatinine reciprocals representing measures of kidney function change ([mg/dL]-1/y), were analyzed in 30Â 621 patients. Based on treatment arms, patients were categorized into 3 groups: placebo (n=10Â 057), atorvastatin 10Â mg daily (n=12Â 763), and 80Â mg daily (n=7801). To assess slopes, mixed-model analyses were performed for each treatment separately, including time in years and adjustment for study. These slopes displayed linear improvement over time in all 3 groups. Slope estimates for patients randomized to placebo or atorvastatin 10Â mg and 80Â mg were 0.009 (0.0008), 0.011 (0.0006), and 0.014 (0.0006) (mg/dL)-1/y, respectively. A head-to-head comparison of atorvastatin 10 and 80Â mg based on data from 1 study ( TNT [Treating to New Targets]; n=10Â 001) showed a statistically significant difference in slope between the 2 doses ( P=0.0009). From a Cox proportional hazards model using slope as a predictor, a significant ( P<0.0001) negative association between kidney function and cardiovascular outcomes was found. Conclusions In patients at risk of or with cardiovascular disease, atorvastatin improved kidney function over time in a dose-dependent manner. In the 3 treatment groups, kidney function improvement was strongly associated with lower cardiovascular risk. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifiers: NCT00327418; NCT00147602; NCT00327691.
PMCID:6512126
PMID: 31020900
ISSN: 2047-9980
CID: 4096792
Cardiovascular revascularization medicine : including molecular interventions. 2019:20(8):632-633.DOI: 10.1016/j.carrev.2019.07.004
Statins for Prevention of Contrast-Associated Acute Kidney Injury: Is the Debate a Moot Point? [Editorial]
PMID: 31420072
ISSN: 1878-0938
CID: 4046462
